Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04951076 · ClinicalTrials.gov registry record · Phase 2

A Phase 2b Study of BNC210 Tablet Formulation in Adults With Post-Traumatic Stress Disorder (PTSD)

A Phase 2 study of Post Traumatic Stress Disorder, sponsored by Bionomics Limited.

Completed
Registry status
Phase 2
Development phase
212
Enrollment target
20
Study locations

NCT04951076 is a Phase 2 study of Post Traumatic Stress Disorder that has completed, run by Bionomics Limited. The registered enrollment target is 212 participants, below the 1,115-participant average among 144 other Post Traumatic Stress Disorder trials with a reported enrollment target (81% lower). The trial reports 20 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04951076, a Phase 2 study of Post Traumatic Stress Disorder, has completed, sponsored by Bionomics Limited.

COMPLETED
Registry status
Phase 2
Development phase
212 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to assess the effects of BNC210 compared to placebo on Post-Traumatic Stress Disorder (PTSD) symptom severity as measured by the Clinician Administered PTSD scale for The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) (CAPS-5) Total Symptom Severity Scores.

Conditions Studied

Post Traumatic Stress Disorder

Interventions

  • DRUG Placebo
  • DRUG BNC210

Study Locations (20)

California

  • ATTUNE Study Clinical Trial Site - Bellflower
  • ATTUNE Study Clinical Trial Site - Beverly Hills
  • ATTUNE Study Clinical Trial Site - Colton
  • ATTUNE Study Clinical Trial Site - Oceanside
  • ATTUNE Study Clinical Trial Site - Orange
  • ATTUNE Study Clinical Trial Site - Temecula

Florida

  • ATTTUNE Study Clinical Trial Site - Jacksonville
  • ATTUNE Study Clinical Trial Site - Lauderhill
  • ATTUNE Study Clinical Trial Site - Miami Lakes
  • ATTUNE Study Clinical Trial Site - Orlando

Kansas

  • ATTUNE Study Clinical Trial Site - Overland Park
  • ATTUNE Study Clinical Trial Site - Prairie Village

New Jersey

  • ATTUNE Study Clinical Trial Site - Berlin
  • ATTUNE Study Clinical Trial Site - Cherry Hill

New York

  • ATTUNE Study Clinical Trial Site - Cedarhurst
  • ATTUNE Study Clinical Trial Site - Staten Island

Massachusetts

  • ATTUNE Study Clinical Trial Site - New Bedford

Nevada

  • ATTUNE Study Clinical Trial Site - Las Vegas

Ohio

  • ATTUNE Study Clinical Trial Site - North Canton

Trial Details

FieldValue
Enrollment Target 212 participants
Start Date 2021-07-27
Est. Completion 2023-08-14
Phase Phase 2

Sponsor

Bionomics Limited

4 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04951076

The ClinicalTrials.gov registry entry for NCT04951076 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 212 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,115-participant average among 144 other Post Traumatic Stress Disorder trials with a reported enrollment target (81% lower). The listed sponsor is Bionomics Limited, which has 4 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Post Traumatic Stress Disorder appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT04951076 reports 20 study locations spanning 9 distinct geographic areas - top geographies include California, Florida, Kansas.

Frequently Asked Questions

What is clinical trial NCT04951076 about?

NCT04951076 is a clinical study titled "A Phase 2b Study of BNC210 Tablet Formulation in Adults With Post-Traumatic Stress Disorder (PTSD)". The purpose of this study is to assess the effects of BNC210 compared to placebo on Post-Traumatic Stress Disorder (PTSD) symptom severity as measured by the Clinician Administered PTSD scale for The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) (CAPS-5) Total Symptom ...

What is the current status of trial NCT04951076?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 212 participants. The study started on 2021-07-27. Estimated completion is 2023-08-14.

What conditions does trial NCT04951076 study?

This clinical trial studies the following conditions: Post Traumatic Stress Disorder.

What interventions are being tested in trial NCT04951076?

The interventions under investigation include: Placebo (DRUG), BNC210 (DRUG).

Who is sponsoring clinical trial NCT04951076?

This trial is sponsored by Bionomics Limited, which has 4 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04951076 being conducted?

This trial has 20 study locations across California, Florida, Kansas, Massachusetts, Nevada. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Post Traumatic Stress Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Post Traumatic Stress Disorder

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.